We are passionate about your business

Dr Lynn Drummond has had a distinguished career in the pharmaceutical and life sciences sectors, spending 16 years as a Managing Director within Investment Banking for Rothschild. Prior to Rothschild, Lynn worked in the Cabinet Office in London as Private Secretary to the Chief Scientific Advisor.

Dr Drummond is currently Chair of the Board of Governors at the University of Hertfordshire; a non-Executive Director and Chair designate at Zotefoams plc and also works as a Board Mentor for Criticaleye. She has held additional Non-Executive Directorships at Venture Life Group plc; RPC Group plc; Infirst Healthcare; Shield Holdings AG; Allocate Software plc; Consort Medical plc; and Alimentary Health Ireland. Lynn has also been Chairman of Trustees for Breast Cancer Haven, and was on the University of Cambridge, Centre for Science and Policy Development Group.

Lynn holds a Bachelor of Science Degree in Chemistry from the University of Glasgow and a PhD in Biochemistry from the University of London. She is a Fellow of the Royal Society of Chemistry, and a Fellow of the Royal Society of Edinburgh.

Sally Ann is responsible for the development of the SBC Campus to its full potential as a world-class science, innovation and business cluster.

Prior to this, Sally Ann was the first Director for Harwell Oxford, where she was responsible for the establishment of the Harwell Enterprise Zone, the European Space Agency and the establishment of the UK Space Satellite Catapult Centre. She was also Director of Colworth Science Park, a leading location for open innovation developed under a joint venture between Unilever and Goodman International property group.  Before coming to SBC, Sally Ann was CEO of Norwich Research Park, a life science cluster of world leading academics, researchers and clinicians.

Sally Ann began her career with Unilever as a management trainee and went on to hold a range of roles across venture capital, technology licensing and strategic alliance management. She has a PhD in molecular biology from the University of Cambridge and is a qualified Chartered Global Management Accountant.

Jon started his career in academia as a member of scientific staff in the Biochemistry Department, Imperial College and then as a Senior Scientific Officer with the Medical Research Council Toxicology Unit. Jon joined Cambridge Antibody Technology (CaT), in 1992 as a Senior Scientist, initially working on several drug discovery projects. Jon then helped establish the CaT process development group before moving across to operational management.  Jon held the post of VP Site General Manager, at what was MedImmune, a wholly-owned subsidiary of AstraZeneca, formed through the merger of CaT and MedImmune where Jon was responsible for leading the site operations of the Cambridge R&D facilities. Jon has held the position of Chair of the Board of One Nucleus and Chief Operating Officer of Iontas, a well-known antibody engineering CRO.

Jon is currently a Scientific and Laboratory Consultant at Coel, a Consultant at Blackpowder Consulting, Chief Operating Officer at ImmuONE, and holds several other directorships and NED appointments.

Jon has a MPhil in molecular biology/cellular pathology, is a Chartered Biologist, a Fellow of the Royal Society of Biology, the Royal Society of Arts and Manufacturing and Fellow of the Institute of Directors.

Professor Jackie Hunter CBE is currently Chair of the Board at the Stevenage Bioscience Catalyst, the UK’s first open innovation biomedical campus. 

Jackie was until recently a Board Director at BenevolentAI and has over thirty years of experience in the bioscience research sector, working across academia and industry, including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline (GSK). BenevolentAI is a British-held company using AI to augment the research capabilities of drug scientists, radically changing the way R&D is done.

Jackie was also Chief Executive of the Biotechnology and Biological Sciences Research Council (BBSRC). She has been recognised by Forbes Magazine as one of the Top 20 Women Advancing AI Research and named in MedicineMaker’s Power List 100 for 2019. She is a member of the Biomedical Board for A*Star in Singapore, the Science Advisory Board for the Data Science Institute at Imperial College London, a Board Director of the UK BioIndustry Association and recently joined the Technology Advisory Board for British Petroleum plc. She is also a visiting Professor at Imperial College and at St George’s Hospital Medical School. She has held Non-Executive Board positions for both private and public companies.

Nick is the Wellcome Trust Observer on the Stevenage Bioscience Catalyst Board.

At Wellcome, Nick is Head of the Priority Area, team with responsibility for a broad portfolio of translational projects across the pharmaceutical and life sciences sector. He is responsible for the discovery & development activities at UK and US R&D hubs across a broad range of disease areas, including creative external partnerships with academia, venture capital firms and incubators. Nick has built a successful portfolio of discovery and clinical assets at all stages of development.

Nick has significant global experience in discovering and developing impactful medicines including ten years at GSK.  Previously, Nick has also pioneered the open innovation agenda in diseases of the developing world and the establishment of the Tres Cantos Open Lab Foundation supporting novel neglected disease drug discovery ideas at the academic-industry interface.

Dr Uday Phadke is the co-founder and CEO of Triple Chasm. Dr Phadke has focused over the last three decades on how science and technology enabled innovation can be translated to deliver commercial impact. Author of two highly respected books, Dr Phadke is the originator of the Triple Chasm Approach, which challenges many of the commonly held perceptions about how innovations are transformed to create commercial, social, and environmental impact.

He is currently Chief Executive of both Cartezia and the Triple Chasm Company and serves on the Board of the UK R&D Society. Dr Phadke is a former Entrepreneur in Residence at the Judge Business School, Cambridge University, and was elected a Fellow of the RSA in 2018.

Graham Rivers is the Vice President Financial Controller Global Commercial for GSK, responsible for overseeing, coordinating and controlling performance, forecast and delivery of GSK Commercial Regions and Central groups. Graham has a long track record of success in GSK, holding very senior leadership positions in finance, IT and procurement.

Graham started out his career as a Research and Development Scientist at Durham University, where he was awarded a Batchelor of Science in Chemistry before going on to join Deloitte as an auditor, and then embarking on his career within GSK in 1998.

Alfie supports the day-to-day operations of Stevenage Bioscience Catalyst campus, including lab and office access, digital onboarding systems, site security, and wider facilities coordination.
He plays a key role in ensuring the smooth running of campus services and is working towards further qualifications in health and safety, including NEBOSH, supporting the wider operations team and customers on site.
Alfie holds A-levels in Computer Science, Business and History, subjects that underpin both his technical understanding and his practical, solutions-focused approach.
Outside of work, he is a keen petrol head and enjoys nothing better than a weekend car show!

Sam Atack is the Operations Director at Stevenage Bioscience Catalyst, he holds strategic and operational responsibility for the overall management and development of the campus estate. His remit includes leadership and oversight of all hard and soft facilities services, encompassing engineering and infrastructure, planned and reactive maintenance, compliance, and lifecycle planning, as well as reception, housekeeping, security, and contracted services. He also leads on all matters relating to Health and Safety, Environmental Management, and the delivery of SBC’s long-term Sustainability objectives.
In his role, Sam provides strategic direction to ensure the resilience, functionality, and future-readiness of the campus, supporting a growing scientific community with a focus on operational excellence, regulatory compliance, and continuous improvement.
Since joining SBC in August 2021, Sam has brought extensive experience in facilities and safety management, developed through senior roles in higher education, research, hospitality, and the charitable sectors. Prior to joining SBC, he held operational leadership positions within the Estates Division at University College London.
He is a Chartered Member of the Institution of Occupational Safety and Health (CMIOSH), a Fellow of the Institute of Workplace and Facilities Management (FIWFM) and has Practitioner Membership of the Institute of Environmental Management and Assessment (PIEMA).

At SBC, Marco is responsible for business development and for supporting the business growth of resident companies. His work includes connecting founders with experts, investors, and pharma partners; organising workshops on topics such as storytelling, negotiation, AI tools, and grant writing; and leading SBC’s accelerator programme called Catalyser, which helps therapeutics startups refine their commercialisation strategies.

Before joining SBC in 2022, Marco was part of the founding team of alternative-protein start-up, Better Dairy. As Head of R&D, he led the science team and helped the start-up grow from pre-seed to £22m Series A investment. As Innovation Lead, he organised and managed the building of a new lab and office facility in East London and helped devise new scientific strategies.

Marco holds a BSc and MSc in Biomedical Engineering with a focus on data science. He also holds a PhD in Synthetic Biology with a focus on protein design. Before joining Better Dairy, he was part of the Entrepreneur First programme.

Sally Ann is responsible for the development of the SBC Campus to its full potential as a world-class science, innovation and business cluster.

Prior to this, Sally Ann was the first Director for Harwell Oxford, where she was responsible for the establishment of the Harwell Enterprise Zone, the European Space Agency and the establishment of the UK Space Satellite Catapult Centre. She was also Director of Colworth Science Park, a leading location for open innovation developed under a joint venture between Unilever and Goodman International property group. Before coming to SBC, Sally Ann was CEO of Norwich Research Park, a life science cluster of world leading academics, researchers and clinicians.

Sally Ann began her career with Unilever as a management trainee and went on to hold a range of roles across venture capital, technology licensing and strategic alliance management. She has a PhD in molecular biology from the University of Cambridge and is a qualified Chartered Global

Laura joined Stevenage Bioscience Catalyst in November 2022, working closely with the CEO, senior leadership and Board to support strategic priorities and the smooth running of the organisation. Her role focuses on people and culture, including staff onboarding, HR processes and the delivery of internal initiatives that support engagement and retention, alongside managing key stakeholder relationships.

Prior to SBC, Laura worked in marketing at Mergermarket Group, now part of Acuris, contributing to campaigns across M&A intelligence and financial news for a global audience.

Liz Hawley is Finance Director at SBC. She is a Chartered Accountant (ACA) with more than 15 years’ experience in finance; specialising in corporate reporting and business partnering in the Construction, healthcare, and Not for Profit sectors.

Liz began her career at PwC before joining News UK. She later spent eight years as Finance Manager at Schüco (UK) Limited. Most recently, she held a senior finance leadership role at St Andrew’s Healthcare, a leading UK mental health charity.

Liz holds a BSc in Geography from the University of Birmingham and qualified as a Chartered Accountant with the ICAEW.

Sureyya has 15 years’ experience across marketing and communications spanning lifestyle, healthcare, education and property.

Her work at SBC focuses on positioning the campus to attract early-stage therapeutics companies and building a connected, collaborative ecosystem. She leads marketing strategy and external profile, working with the Executive Team on lead generation, with an emphasis on retention, scaling and stakeholder engagement. She shapes the campus brand, translating complex science into clear, commercially relevant narratives.

Sureyya holds a degree in English Literature (Newcastle University; Birkbeck, University of London), a postgraduate diploma in news writing (NCTJ, Harlow), and a Professional Certificate in Marketing (Chartered Institute of Marketing). She has also studied storywriting (Faber Academy, London).

Paula Medford joined Stevenage Bioscience Catalyst as Financial Accountant in September 2019. She is AAT qualified with extensive experience covering financial due diligence and control having worked in the Film Media, Oil and Gas industries and most recently Business Property Services supporting Biotech start-ups and growth companies.

Ela Nowak joined Stevenage Bioscience Catalyst in November 2024 as Technical and Safety Services Manager. With a strong background in chemical technology and biomedical research, Ela has cultivated a career supporting advanced laboratory operations and ensuring safety in cutting-edge scientific environments.
Previously, Ela served as Laboratory Manager at Achilles Therapeutics, where she ensured high standards of safety, equipment reliability, and operational efficiency. Her experience spans laboratory supervision, health and safety leadership, and fostering environments conducive to innovative research and technological advancements.

Alex joined the SBC Facilities team in August 2017. Before joining SBC, Alex was U-18 Hertfordshire County Cricket coach. He was the Captain of the Hertfordshire and Middlesex County Cricket teams.

As the Operations manager, Alex brings a strong focus on facilities management, project delivery, sustainability, and data analytics. Alex’s role supports the smooth operation of the campus, ensuring an efficient, secure, and future-ready environment for our occupiers. He is passionate about driving continuous improvement through data-led decision making and promoting sustainable practices across our operations.

He is a member of the Institute of Workplace and Facilities Management (MIWFM) and a Member of the Association for Project Management (MAPM).

Roger Smith joined the Stevenage Bioscience Catalyst team in February 2012. Roger started his working life as a farmer but soon progressed into farm management, ultimately being responsible for 2,000 individuals and 4,000 hectares of agriculture. This acute understanding, and incredible facility for organisation, gives our Catalyst a head start in the Pharma community.
Roger is an essential part of day-to-day operations, and the buildings would not function without him. Roger has strong relationships with all our Occupiers and will assist in all building matters Occupiers are not responsible for.

Andrew Waters joined Stevenage Bioscience Catalyst as Chief Financial Officer in September 2023 and moved into the role of Interim CEO in 2025.

Andrew is a chartered accountant with over 25 years’ experience, mostly gained within the Life Sciences industry. His career has included 16 years within GSK in a number of Finance positions as well as a series of CFO roles in both private and public companies. Andrew has a Physics degree from Imperial College and qualified as a chartered accountant with Price Waterhouse.

He has wide-ranging experience across start-ups, SMEs, PLC, fund raising, Manufacturing, Life Sciences and Buy & Build. Senior leadership posts have included Regional Finance Director, GSK; Co-founder and CFO of private-equity funded pharmaceutical and consumer healthcare start-up Infirst Healthcare and CFO of public life sciences company Venture Life Group plc.